{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:35:15Z","timestamp":1791020115132,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Intravenous immunoglobulin G (IVIG) is used to treat idiopathic thrombocytopenic purpura (ITP). Although many patients benefit from IVIG, some are refractory to this therapy. ITP is characterized by platelet clearance mediated primarily by antiplatelet antibodies against GPIIbIIIa and\/or the GPIb\u03b1 complex. These 2 groups of antibodies may induce ITP through different mechanisms. We tested the hypothesis that IVIG may not be equally effective in preventing ITP caused by anti-GPIIbIIIa versus anti-GPIb\u03b1 antibodies in mice. Thrombocytopenia was induced in BALB\/c mice using monoclonal antibodies against either mouse GPIIbIIIa (JON1, JON2, and JON3) or GPIb\u03b1 (p0p3, p0p4, p0p5, p0p9, and p0p11). Pretreatment with IVIG significantly ameliorated ITP in all anti-GPIIbIIIa\u2013injected animals. Conversely, IVIG failed to prevent ITP in all anti-GPIb\u03b1\u2013treated mice, except for p0p4. These results were repeated in C57BL\/6 mice, and with different IVIG preparations. These data in mice suggest that patients with ITP mediated by anti-GPIb\u03b1 antibodies may be less responsive to IVIG treatment.<\/jats:p>","DOI":"10.1182\/blood-2005-06-009761","type":"journal-article","created":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T00:54:16Z","timestamp":1144371256000},"page":"943-946","source":"Crossref","is-referenced-by-count":111,"title":["Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIb\u03b1 antibodies"],"prefix":"10.1182","volume":"108","author":[{"given":"Michelle Lee","family":"Webster","sequence":"first","affiliation":[{"name":"From the Canadian Blood Services, Ottawa, ON, Canada; the Toronto Platelet Immunobiology Group, and Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada; the Department of Laboratory Medicine and Pathobiology, and the Department of Medicine, University of Toronto, ON, Canada; the Institute of Clinical Biochemistry and Pathobiochemistry and Rudolf Virchow Center for Experimental Biomedicine, University of Wu\u0308rzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Sayeh","sequence":"additional","affiliation":[{"name":"From the Canadian Blood Services, Ottawa, ON, Canada; the Toronto Platelet Immunobiology Group, and Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada; the Department of Laboratory Medicine and Pathobiology, and the Department of Medicine, University of Toronto, ON, Canada; the Institute of Clinical Biochemistry and Pathobiochemistry and Rudolf Virchow Center for Experimental Biomedicine, University of Wu\u0308rzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Crow","sequence":"additional","affiliation":[{"name":"From the Canadian Blood Services, Ottawa, ON, Canada; the Toronto Platelet Immunobiology Group, and Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada; the Department of Laboratory Medicine and Pathobiology, and the Department of Medicine, University of Toronto, ON, Canada; the Institute of Clinical Biochemistry and Pathobiochemistry and Rudolf Virchow Center for Experimental Biomedicine, University of Wu\u0308rzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingguo","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Canadian Blood Services, Ottawa, ON, Canada; the Toronto Platelet Immunobiology Group, and Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada; the Department of Laboratory Medicine and Pathobiology, and the Department of Medicine, University of Toronto, ON, Canada; the Institute of Clinical Biochemistry and Pathobiochemistry and Rudolf Virchow Center for Experimental Biomedicine, University of Wu\u0308rzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Nieswandt","sequence":"additional","affiliation":[{"name":"From the Canadian Blood Services, Ottawa, ON, Canada; the Toronto Platelet Immunobiology Group, and Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada; the Department of Laboratory Medicine and Pathobiology, and the Department of Medicine, University of Toronto, ON, Canada; the Institute of Clinical Biochemistry and Pathobiochemistry and Rudolf Virchow Center for Experimental Biomedicine, University of Wu\u0308rzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Freedman","sequence":"additional","affiliation":[{"name":"From the Canadian Blood Services, Ottawa, ON, Canada; the Toronto Platelet Immunobiology Group, and Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada; the Department of Laboratory Medicine and Pathobiology, and the Department of Medicine, University of Toronto, ON, Canada; the Institute of Clinical Biochemistry and Pathobiochemistry and Rudolf Virchow Center for Experimental Biomedicine, University of Wu\u0308rzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyu","family":"Ni","sequence":"additional","affiliation":[{"name":"From the Canadian Blood Services, Ottawa, ON, Canada; the Toronto Platelet Immunobiology Group, and Department of Laboratory Medicine, St Michael's Hospital, Toronto, ON, Canada; the Department of Laboratory Medicine and Pathobiology, and the Department of Medicine, University of Toronto, ON, Canada; the Institute of Clinical Biochemistry and Pathobiochemistry and Rudolf Virchow Center for Experimental Biomedicine, University of Wu\u0308rzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019102210320330900_REF1","doi-asserted-by":"crossref","unstructured":"Kelton JG, Bussel JB. Idiopathic immune thrombocytopenic purpura: an update. Semin Hematol.2000;37: 219-221.","DOI":"10.1016\/S0037-1963(00)90099-4"},{"key":"2019102210320330900_REF2","doi-asserted-by":"crossref","unstructured":"McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol.2000;37: 239-248.","DOI":"10.1016\/S0037-1963(00)90102-1"},{"key":"2019102210320330900_REF3","unstructured":"Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med.1951;38: 1-10."},{"key":"2019102210320330900_REF4","doi-asserted-by":"crossref","unstructured":"Woods VL Jr, McMillan R. Platelet autoantigens in chronic ITP. Br J Haematol.1984;57: 1-4.","DOI":"10.1111\/j.1365-2141.1984.tb08493.x"},{"key":"2019102210320330900_REF5","doi-asserted-by":"crossref","unstructured":"He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood.1994;83: 1024-1032.","DOI":"10.1182\/blood.V83.4.1024.1024"},{"key":"2019102210320330900_REF6","doi-asserted-by":"crossref","unstructured":"Beardsley DS, Ertem M. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci.1998;19: 237-244.","DOI":"10.1016\/S0955-3886(98)00037-X"},{"key":"2019102210320330900_REF7","doi-asserted-by":"crossref","unstructured":"McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol.2003;25: S57-S61.","DOI":"10.1097\/00043426-200312001-00013"},{"key":"2019102210320330900_REF8","doi-asserted-by":"crossref","unstructured":"Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood.2000;96: 2520-2527.","DOI":"10.1182\/blood.V96.7.2520"},{"key":"2019102210320330900_REF9","doi-asserted-by":"crossref","unstructured":"Amital H, Swissa M, Bar-Dayan Y, Buskila D, Shoenfeld Y. New therapeutic avenues in autoimmunity. Res Immunol.1996;147: 361-376.","DOI":"10.1016\/0923-2494(96)82045-1"},{"key":"2019102210320330900_REF10","doi-asserted-by":"crossref","unstructured":"Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood.1993;82: 1415-1421.","DOI":"10.1182\/blood.V82.5.1415.1415"},{"key":"2019102210320330900_REF11","doi-asserted-by":"crossref","unstructured":"Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci.1998;153: 203-214.","DOI":"10.1016\/S0022-510X(97)00292-X"},{"key":"2019102210320330900_REF12","doi-asserted-by":"crossref","unstructured":"Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apheresis Sci.2003;28: 249-255.","DOI":"10.1016\/S1473-0502(03)00043-0"},{"key":"2019102210320330900_REF13","doi-asserted-by":"crossref","unstructured":"Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol.2002;118: 933-944.","DOI":"10.1046\/j.1365-2141.2002.03669.x"},{"key":"2019102210320330900_REF14","doi-asserted-by":"crossref","unstructured":"Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticuloendothelial system function and ameliorates murine passiveimmune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol.2001;115: 679-686.","DOI":"10.1046\/j.1365-2141.2001.03136.x"},{"key":"2019102210320330900_REF15","doi-asserted-by":"crossref","unstructured":"Hiraiwa A, Nugent DJ, Milner ECB. Sequence analysis of monoclonal antibodies derived from a patient with idiopathic thrombocytopenic purpura. Autoimmunity.1990;8: 107-113.","DOI":"10.3109\/08916939008995728"},{"key":"2019102210320330900_REF16","doi-asserted-by":"crossref","unstructured":"Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood.2003;102: 887-895.","DOI":"10.1182\/blood-2002-05-1475"},{"key":"2019102210320330900_REF17","doi-asserted-by":"crossref","unstructured":"Woods VL Jr, Kurata Y, Montgomery RR, et al. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood.1984;64: 156-160.","DOI":"10.1182\/blood.V64.1.156.156"},{"key":"2019102210320330900_REF18","doi-asserted-by":"crossref","unstructured":"Rice L, Nichol J, McMillan R, Roskos L, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol.2001;68: 210-214.","DOI":"10.1002\/ajh.1181"},{"key":"2019102210320330900_REF19","doi-asserted-by":"crossref","unstructured":"Szatkowski NS, Kunicki TJ, Aster RH. Identification of glycoprotein Ib as a target for autoantibody in idiopathic (autoimmune) thrombocytopenic purpura. Blood.1986;67: 310-315.","DOI":"10.1182\/blood.V67.2.310.310"},{"key":"2019102210320330900_REF20","doi-asserted-by":"crossref","unstructured":"Yanabu M, Nomura S, Fukuroi T, et al. Synergistic action in platelet activation induced by an anti-platelet autoantibody in ITP. Br J Haematol.1991;78: 87-93.","DOI":"10.1111\/j.1365-2141.1991.tb04387.x"},{"key":"2019102210320330900_REF21","doi-asserted-by":"crossref","unstructured":"Olsson A, Andersson PO, Tengborn L, Wadenvik H. Serum from patients with chronic idiopathic thrombocytopenic purpura frequently affect the platelet function. Thromb Res.2002;107: 135-139.","DOI":"10.1016\/S0049-3848(02)00260-8"},{"key":"2019102210320330900_REF22","unstructured":"Jy W, Hortsman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med.1992;119: 334-345."},{"key":"2019102210320330900_REF23","doi-asserted-by":"crossref","unstructured":"Ozaki Y, Asazuma N, Suzuki-Inoue K, Berndt MC. Platelet GPIb-IX-V-dependent signaling. J Thromb Haemost.2005;3: 1745-1751.","DOI":"10.1111\/j.1538-7836.2005.01379.x"},{"key":"2019102210320330900_REF24","doi-asserted-by":"crossref","unstructured":"Itkin Y, Trujillo T. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Phamacotherapy.2005;25: 886-892.","DOI":"10.1592\/phco.2005.25.6.886"},{"key":"2019102210320330900_REF25","doi-asserted-by":"crossref","unstructured":"Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol.2004;83: 661-665.","DOI":"10.1007\/s00277-004-0895-2"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/3\/943\/1281919\/zh801506000943.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/3\/943\/1281919\/zh801506000943.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T16:20:49Z","timestamp":1571761249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/108\/3\/943\/22347\/Relative-efficacy-of-intravenous-immunoglobulin-G"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-009761","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}